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Abstract 
Background: HIV‑1 replication results in mitochondrial damage that is enhanced during antiretroviral therapy (ART). 
The onset of HIV‑1 replication is regulated by viral protein Tat, a 101‑residue protein codified by two exons that elon‑
gates viral transcripts. Although the first exon of Tat (aa 1–72) forms itself an active protein, the presence of the second 
exon (aa 73–101) results in a more competent transcriptional protein with additional functions.
Results: Mitochondrial overall functions were analyzed in Jurkat cells stably expressing full‑length Tat (Tat101) or 
one‑exon Tat (Tat72). Representative results were confirmed in PBLs transiently expressing Tat101 and in HIV‑infected 
Jurkat cells. The intracellular expression of Tat101 induced the deregulation of metabolism and cytoskeletal proteins 
which remodeled the function and distribution of mitochondria. Tat101 reduced the transcription of the mtDNA, 
resulting in low ATP production. The total amount of mitochondria increased likely to counteract their functional 
impairment. These effects were enhanced when Tat second exon was expressed.
Conclusions: Intracellular Tat altered mtDNA transcription, mitochondrial content and distribution in CD4+ T cells. 
The importance of Tat second exon in non‑transcriptional functions was confirmed. Tat101 may be responsible for 
mitochondrial dysfunctions found in HIV‑1 infected patients.
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Background
Human immunodeficiency virus type 1 (HIV-1) infec-
tion is characterized by a progressive depletion of CD4+ 
T lymphocytes in the peripheral blood and lymphoid 
organs which finally leads to the onset of acquired 
immune deficiency syndrome [1]. HIV-1 replication 
results in the chronic activation of the immune system 
and consequently in premature immunosenescence [2]. 
During normal aging, mitochondrial DNA (mtDNA) 
accumulate mutations induced through the direct exposi-
tion to reactive oxygen species (ROS) and deficient repair 
systems [3, 4]. Accordingly, T CD4+ lymphocytes from 
naïve HIV-1 infected patients show mtDNA depletion 
along with impaired activity of the respiratory chain com-
ponents, enhanced oxidative damage and decrease mito-
chondrial transmembrane potential (∆ψm) [5, 6]. These 
alterations may be explained by a deregulated expression 
of nuclear and mitochondrial encoded proteins such as 
Prohibitin, Heat shock protein 60 (Hsp60) and complex-I 
subunit NDUF6 [7, 8]. Furthermore, it is well-known that 
the antiretroviral treatment (ART) against HIV-1, in par-
ticular nucleoside-analogue inhibitors (NRTIs), induces 
mitochondrial toxicity [9, 10] due to the inhibition of 
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mtDNA polymerase γ [11]. In summary, HIV-1 infection 
triggers mitochondria impairment aside from the toxicity 
of the treatment and therefore it may enhance the sus-
ceptibility for the clinical onset of ART side-effects.
HIV-1 Tat is a 101-residue protein codified by two 
exons that promotes the efficient elongation of the viral 
transcripts through the binding to RNA polymerase II 
(RNAPII) complex and the recruitment of cellular elon-
gation factors [12]. The first exon of Tat includes amino 
acids (aa) 1–72 and encodes an active protein that par-
tially retains the elongation ability of full-length Tat [13]. 
The second exon is codified by amino acids 73–101 and 
its expression within the protein results in a more com-
petent transcriptional protein with additional functions 
independent of transcription such as control of apopto-
sis [14, 15]. Tat can be released from infected cells and 
up-taken by non-infected adjacent cells. Extracellular 
and intracellular Tat frequently have opposite actions, 
as Tat expressed inside the host-infected cells can delay 
apoptosis upon FasL-challenge [14–17], but it is a potent 
death inductor in its soluble form [18, 19]. Although loss 
of ∆ψm and increased levels of ROS has been found after 
Tat extracellular exposure [20–22], few data are avail-
able about the effect of intracellular Tat on mitochon-
dria functions. Our group showed that intracellular Tat 
deregulated the expression of proteins required for mito-
chondrial membrane stabilization as HSP and Prohibitin 
[15].
In this work, we describe the single influence of intra-
cellular HIV-1 Tat protein on mitochondria overall func-
tions in CD4+ T cells, showing that Tat101 remodeled 
mitochondria distribution and enhanced the mitochon-
dria content probably to compensate the mtDNA tran-
scription impairment. These effects were enhanced when 
Tat second exon was expressed.
Results
Tat101 deregulated the expression of cellular proteins 
related to metabolism and oxidative stress
To describe the role of Tat on mitochondria, Jurkat cells 
stably expressing Tat72 (Jurkat-Tat72) or Tat101 (Jurkat-
Tat101) protein were used as a proper model of CD4+ 
T lymphocytes as previously shown [15]. The proteome 
of Jurkat-Tat101 and Jurkat-Tat72 was analyzed by liq-
uid chromatography–mass spectrometry (LC–MS)/MS 
in basal conditions, in comparison with control cells. 
A comparative analysis of the LC–MS/MS proteome 
showed that the intracellular expression of Tat101 dereg-
ulated the expression of 19 cellular proteins involved in 
metabolism and control of oxidative stress (Table  1). 
A total of 14 proteins were up-regulated, representing 
73.68  % of the deregulated proteins. To a lower extend, 
these proteins were also deregulated in Jurkat-Tat72 
cells. Proteins with major functions in glycolysis included 
alpha-enolase (ENO1), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), l-lactate dehydrogenase 
(LDHB) and pyruvate kinase isozymes M1/M2 (PKM2), 
which were, respectively 17.9-, −11.4-, 10.4- and 36.8-
fold expressed in Jurkat-Tat101 cells versus control cells. 
It was found an overall up-regulation of proteins from 
the thioredoxin and glutaredoxin redox superfamilies. 
These proteins included protein disulfide-isomerase 
(P4HB), thioredoxin domain-containing protein 17 
(TXDC17), protein disulfide-isomerase A4 (PDIA4) and 
SH3 domain-binding glutamic acid-rich-like protein 3 
(SH3BGR3), which were, respectively, 2.5-, 2.8-, 5.2-, and 
8.4-fold deregulated. Other proteins related to the oxida-
tive metabolism such as superoxide dismutase (SOD1) 
and peroxiredoxin-1 (PRDX1) were 3.3- and 7.8-fold up-
regulated in Jurkat-Tat101 cells. Most of these proteins 
were functionally interconnected as it was observed after 
analyzing the predicted interactions by STRING data-
base (Fig. 1).
Tat101 increased citrate synthase activity and lactate levels 
but reduced the activity of respiratory complexes
Citrate synthase levels are routinely used as a marker 
mitochondrial content [23]. In Jurkat-Tat101 cells, cit-
rate synthase activity increased 4.75-fold regarding con-
trol cells (p  <  0.05), whereas it increased only 2.75-fold 
in Jurkat-Tat72 (Fig.  2a). Although the average amount 
of mitochondria was increased, the overall production 
of ATP was significantly reduced in Jurkat-Tat101 cells 
(p  <  0.01) (Fig.  2b), suggesting that these mitochondria 
were not functionally competent. To test this hypoth-
esis, the enzyme activity of complex-I and complex-V 
of the respiratory chain was measured, using citrate 
synthase activity to normalize mitochondrial content. 
Complex-I and complex-V activities were 2.85- and 2.27-
fold reduced, respectively, in Jurkat-Tat101 (p  <  0.05). 
Complex-I and complex-V were only 1.35- and 1.85-fold 
reduced in Jurkat-Tat72, respectively (Fig. 2c).
As the function of complex-I and complex-V com-
plexes was impaired in Jurkat-Tat101 cells and ATP pro-
duction was reduced but not completely stopped, aerobic 
glycolysis was studied as a complementary energy source 
in Jurkat-Tat101 cells. Aerobic glycolysis is a metabolic 
program in which the lactate production occurs in the 
presence of oxygen [24, 25]. Intracellular levels of lactate 
were measured under aerobic conditions and both Jurkat-
Tat101 and Jurkat-Tat72 cells showed a similar increase 
of 2.0-fold (p  <  0.05) (Fig.  2d, left graph). A slight non-
significant increase of 1.25- and 1.42-fold of lactate lev-
els was found in the culture medium of Jurkat-Tat72 and 
Jurkat-Tat101 cells, respectively, in comparison to control 
cells (Fig. 2d, right graph).
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Table 1 Selection of mitochondrial-related proteins which showed at least a ±2.0-fold deregulation in Jurkat-Tat101 ver-
sus control cells




Biological process Peptide sequence X-corr
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PEBP1 Phosphatidylethanola‑
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Enhanced ROS production was counteracted 
by glutathione system in Jurkat-Tat cells
A enhanced production of ROS in productively and latently 
HIV-1 infected CD4+ T cells has been described [5]. 
Intracellular levels of ROS were measured using dichloro-
fluorescein diacetate (DCF-DA) staining method [26]. 
Immunofluorescence analysis showed that 35.0 % of Jurkat-
Tat101 cells showed high DCF-DA signal, whereas both 
Jurkat-Tat72 and control cells showed only 15 % of highly 
stained cells (Fig.  3a). Acquisition conditions remained 
and a representative field of living Jurkat-Tat72 and Jurkat-
Tat101 is shown. Similarly, flow cytometry quantification 
of the geometry mean (G-mean) of green fluorescence 
increased 1.8-fold in Jurkat-Tat101 and 1.4-fold in Jurkat-
Tat72 cells, regarding control cells (p < 0.01) (Fig. 3b).
Glutathione is an abundant antioxidant that mostly 
exits in its reduced form (GSH). A small percentage of 
the glutathione is oxidized (GSSG) and acts as an indi-
cator of oxidative stress. The intracellular levels of GHS 
and GSSG were enhanced, respectively 2.2-fold and a 1.8-
fold in Jurkat-Tat101 (p < 0.005 and p < 0.05) (Fig. 3c). In 
Jurkat-Tat72 cells, the increase of glutathione levels was 
lower than in Jurkat-Tat101 cells and did not reach statis-
tical significance. The GSH/GSSG ratio that measures the 
cellular oxidative stress [27] remained unaltered in Jurkat 
cells expressing any isoform of Tat protein.
Intracellular expression of Tat101 increased basal 
apoptosis
The intracellular expression of Tat101 protein delays 
Fas-mediated apoptosis during HIV-1 infection in 
CD4+ T lymphocytes [15]. In this work, we show that 
the percentage of cells displaying a typical apoptotic 
phenotype, i.e. morphological disintegration and bub-
bling of the plasma membrane, increased 2.0-fold in 
Jurkat-Tat101 cells and to a lesser extent also in Jurkat-
Tat72 cells, vs control cells (Fig.  4a). It was observed 
in basal conditions and in the absence of activation or 
death stimuli. Selected cells with representative living 
and apoptotic phenotypes are shown in Fig.  4b. Acti-
vation of the effector caspase-3/-7 under basal condi-
tions correlated with apoptotic phenotypes and it was 
1.8- and 2.0-fold higher in Jurkat-Tat72 and Jurkat-
Tat101 cells, respectively, than in control cells (Fig. 4c) 
(p < 0.05).
Apoptosis commitment was measured by quantifying 
externalization of phosphatidylserine (PS) in Annexin-
V stained cells and subsequent flow cytometry analysis, 
showing a 1.4-fold increase in Jurkat-Tat101 versus con-
trol cells (p < 0.05) (Fig. 4d). As increased ROS produc-
tion occurred occurs during cell death, co-localization of 
intracellular ROS and PS externalization was studied in 
control and Jurkat-Tat expressing cells doubled stained 
with DCF-DA and Annexin-V (Fig. 4e). Around 50 % of 
apoptosis-committed cells expressed intracellular ROS 
(Fig.  4e, left panel). However, G-mean of green fluores-
cence increased 1.8-fold in Jurkat-Tat101 cells doubly 
stained for ROS and apoptosis, regarding control cells 
(p  <  0.01) (Fig.  4e, right panel). These data support the 
enhancement of intracellular ROS and apoptosis inde-
pendently showed in Figs. 3 and 4 (panels from a to d), 
respectively.
Table 1 continued
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GAPDH Glyceraldehyde‑3‑phos‑
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Proteins were detected by mass spectrometry in total protein extracts. All peptides detected showed 95 % probability for protein expression and a minimum cross‑
correlation (X‑Corr) value of 1.75
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Tat101 reduced the transcription of mtDNA encoded genes
A unique feature of mitochondria is that they contain 
their own 16-kb genome that encodes mitochondria 
components including 13 subunits of the mitochondria 
respiratory chain essential for the mitochondrial oxi-
dative phosphorylation (OXPHOS) [28, 29]. The tran-
scription of six mtDNA encoded genes was studied in 
Jurkat-Tat expressing cells (Fig. 5a). These genes included 
components of the respiratory chain complex-I, com-
plex-III and complex-IV and were NADH-ubiquinone 
oxidoreductase chain 2 (MTND-2), NADH-ubiquinone 
oxidoreductase chain 5 (MTND-5), NADH-ubiquinone 
oxidoreductase chain 6 (MTND-6), cytochrome c oxi-
dase subunit 2 (COX-II), cytochrome c oxidase subu-
nit 3 (MTCO-3), and cytochrome b (MT-CYB). The 
intracellular expression of Tat101 protein resulted in 
a significant reduction of more than 6.0-fold in both 
COX-II and MTND-2 mRNA levels (p < 0.005) (Fig. 5a). 
In Jurkat-Tat72 cells, COX-II and MTND-2 mRNA 
levels were 3.0-fold reduced (p  <  0.05). Although to a 
lower extend, the expression of other mtDNA encoded 
genes were also significantly reduced in Jurkat-Tat101. 
MTND-5, MTND-6, MT-CYB andMTCO-3 mRNAs 
levels were around 1.5-fold reduced in Jurkat Tat-101 
cells (p  <  0.005 and p  <  0.001) but not in Jurkat-Tat72 
cells (Fig.  5a). These data show the down-regulation of 
mtDNA transcription.
The control of gene expression from mtDNA is directed 
by nuclear-encoded genes as respiratory factor 1 (NRF-1) 
and mitochondrial transcription factor A (TFAM) [30]. 
TFAM mRNA expression was 1.75-fold reduced in Jur-
kat-Tat101 cells (Fig. 5b) (p < 0.05). No significant differ-
ences were found in the expression of NRF-1 mRNA in 
Jurkat-Tat101 cells but the levels of NRF-1 mRNA were 
slightly enhanced in Jurkat-Tat72cells (Fig.  5b). mRNAs 
levels of nuclear-encoded genes involved in mitochon-
drial fusion and fission were analyzed and there were 
not significant changes in the expression of MFN2 and 
DNML1 mRNAs (Fig. 5c).
Intracellular Tat101 enhanced the expression 
of nuclear-encoded mitochondrial genes
Intracellular Tat101 protein is known to profoundly 
deregulate gene expression in T lymphocytes [14, 31]. 
Therefore the effect of Tat101 protein in the transcrip-
tion of nuclear-encoded genes required for mitochon-
dria functions was intensely described. A commercial 
RT-PCR-based array was used to compare the expres-
sion of 84 mitochondrial genes, which were nuclear-
encoded, in Jurkat-Tat101 cells versus control cells. 
Table  2 shows CT values and the relative expression of 
each gene in Jurkat-Tat101 versus control cells after 
normalizing to the housekeeping gene expressions and 
analyzing with the 2−∆∆Ct formula. Genes showing CT 
values equal or higher than 30 cycles or undetermined 
were not considered for additional analysis and there-
fore only the expression of 77 genes was studied. The 
expression levels of 67 genes were increased at least 
+1.5-fold in Jurkat-Tat101 cells, suggesting a general-
ized up-regulation of mitochondrial-related genes. These 
genes represent 88.5 % of the mitochondrial genes stud-
ied. A higher cutoff of ∓2.0-fold change yield 17 genes 
upregulated in Jurkat-Tat101 cells (Fig.  6a). There was 
an enhanced expression of eight members from mito-
chondrial solute carrier family 25 (SLC25), a superfam-
ily of proteins that shuttle metabolites, nucleotides, and 
cofactors through the mitochondrial inner membrane 
including the exchange of cytoplasmic ADP with mito-
chondrial ATP [32]. For example, levels of SLC25A23 and 
SLC25A19 increased 2.43- and 3.28-fold, respectively. 
Other mitochondrial transporters deregulated included 
metaxin 2 (MTX2), involved in importing proteins into 
mitochondria [33], uncoupling protein 3 (UCP3), a 
Fig. 1 Network of predicted interactions between mitochondria‑
related proteins deregulated in Jurkat‑Tat101. Medium confidence 
score level was 0.400. Data supporting protein–protein interactions 
derived from experimental studies (dark purple lines), homology (light 
purple lines), databases (light blue lines), text mining (light green lines), 
concurrence (dark blue lines) and co‑expression (black lines). Node 
colour is arbitrary. Differences in protein levels are specified in Table 1
Page 6 of 24Rodríguez‑Mora et al. Retrovirology  (2015) 12:78 
proton transporter resulting in OXPHOS uncoupling also 
known as SLC25a9 [34], and translocase of inner mito-
chondrial membrane 9 (TIMM9), a chaperone involved 
in the import of transmembrane proteins [35], which 
were respectively 3.68-, 2.69- and 2.23-fold enhanced. 
The functional interconnection of these proteins was 
predicted in STRING database and is shown in Fig.  6b. 
These data suggest an increased expression of nuclear-
encoded mitochondrial genes in Jurkat-Tat101 cells and 
confirm proteome results showed in Table 1 and Fig. 1.
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Fig. 2 Quantification of citrate synthase activity, mitochondria respiratory capacity and lactate levels in Jurkat‑Tat101 cells. a Activity of the citrate 
synthase measured with commercial enzymatic assays in Jurkat‑Tat72 (JJ‑Tat72), Jurkat‑Tat101 (JJ‑Tat101) vs control cells. One citrate unit is equiva‑
lent to a μmole/mL/min. b ATP production was measured using a chemiluminescence‑based assay. c Activity of the complex‑I and complex‑V of 
the respiratory chain was measured in Jurkat‑Tat72, Jurkat‑Tat101 and control cells in mg/mL/min and it was normalized according to mitochondria 
amount indirectly measured as the activity of the citrate synthase enzyme. d Lactate levels were measured in intracellular and supernatant samples 
and concentration was expressed in ng/μl (left and right panels, respectively) from Jurkat‑Tat72, Jurkat‑Tat101 vs control cells. All data shown are 
media and standard error of the mean (SEM) from at least three independent experiments. Statistical significance was calculated by Kruskal–Wallis 
test and post hoc multiple comparisons were performed with Dunn’s multiple comparison analysis (*p < 0.05 and **p < 0.01 vs control)
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Intracellular Tat101 deregulated the expression 
of cytoskeleton proteins and activated small GTPases
The interactions between mitochondria and the cytoskel-
eton influence mitochondrial functions including respira-
tory activity, fusion/fission processes and ROS biogenesis 
[36, 37]. Therefore, the expression of cytoskeleton-related 
proteins was analyzed by LC–MS/MS and predicted pro-
tein interactions were analyzed by STRING database 
(Fig. 7a). Jurkat-Tat101 cells, and to a lesser extent Jurkat-
Tat72 cells, showed the deregulation of 20 cytoskeleton-
related proteins (Table  3). Only five deregulated proteins 
were tubulin-related. Fifteen actin-related proteins were 
altered in Jurkat-Tat101 cells. Three of these proteins were 
involved in small-GTPase signal transduction, includ-
ing Rho GDP-dissociation inhibitor 2 (ARHGDIB) and 
GDP dissociation inhibitor beta protein (GDI2), which 
were −10.0- and +2.0-fold deregulated. Furthermore, the 
activation of RhoA and Rac1 GTPase increased 22.38- 
and 4.67-fold in Jurkat-Tat101 (p < 0.005) but not in Jur-
kat-Tat72 cells (Fig.  7b), in comparison to control cells. 
Non-significant differences were found in the activation 
of Cdc42 (Fig. 7c). Finally, cells were stained with an anti-
body against tubulin to elucidate the cellular shape. Most 
Jurkat-Tat101 cells showed polarized shape, whereas non-
polarized and typically round-shape lymphocytes were 
observed in Jurkat-Tat72 and control cells (Fig.  7d). The 
analysis of migration ability showed that Jurkat-Tat101 
cells migrated spontaneously 1.5-fold more than Jurkat-
Tat72 and control cells (Fig. 7e).
Intracellular Tat101 increased mitochondrial amount 
and polarized its distribution
Because mitochondria are transported to the uropod to 
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Fig. 3 Intracellular ROS generation and glutathione levels in Jurkat‑Tat101 cells. a Microscopy analysis of intracellular ROS levels measured by 
DCF‑DA staining method. Representative fields of living Jurkat‑Tat72, Jurkat‑Tat101 and control cells are shown. Acquisition conditions remained 
the same for each cellular type. The graph shows the number of cells with saturated signal for green laser, from three independent experiments. b 
Cytometry analysis of DCF‑DA stained cells. Graph shows G‑mean of green fluorescence intensity of the living cell population from three independ‑
ent experiments. c Intracellular concentration of reduced (GSH), oxidized (GSSG) and ratio of total glutathione (GSH/GSSG) were measured in Jurkat‑
Tat72, Jurkat‑Tat101 and control cells. Data shown are media and SEM from at least three independent experiments. Kruskal–Wallis test with Dunn’s 
Multiple Comparison post hoc analysis was performed for statistical analysis (*p < 0.05 and ***p < 0.001 vs control)
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migration [38–40] and Jurkat-Tat101 cells showed an 
overall cellular polarized shape, the distribution of the 
mitochondria network was studied. The mitochondria 
network of Jurkat-Tat101 and control cells was analyzed 
after incubating with Mitotracker and DAPI. Two differ-
ent phenotypes, which included a homogeneous and a 
polarized distribution of the mitochondria network, were 
identified (Fig. 8a). The overall presence of the polarized 
phenotype increased up to 50  % in Jurkat-Tat101 cells 
whereas in control cells reached 9.5 %. These phenotypes 
corresponding to homogeneous and polarized distribu-
tion of the mitochondria network were also identified in 
Jurkat-Tat101 cells by electron microscopy (Fig. 8b). The 
re-distribution of mitochondria at one edge of the cell 
a
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Fig. 4 Apoptosis induction in non‑stimulated Jurkat‑Tat101 cells. a Percentage of Jurkat‑Tat72, Jurkat‑Tat101 and control cells showing an apop‑
totic phenotype from three independent experiments analyzed by confocal microscopy. b Representative images of living and apoptotic cells. 
Cells were fixed and the nuclei were stained with Dapi. c Caspase‑3/‑7 activation was measured by a chemiluminiscence‑based test in Jurkat‑Tat72, 
Jurkat‑Tat101 and control cells under basal conditions. Relative luciferase units (RLUs) after total protein normalization are shown. d Percentage 
of apoptosis committed cells expressing external phosphatidylserine. The graph shows the cytometry analysis of Annexin‑V‑PE stained cells. e 
Cytometry analysis of doubly stained cells for Annexin‑V‑PE and DCF‑DA‑FITC. Graph on the left shows the percentage of double stained cells. Graph 
on the right shows G‑mean of green fluorescence intensity in double stained cells. All graphs show media and SEM from at least three independent 
experiments. Kruskal–Wallis test with Dunn’s multiple comparison post hoc analysis was performed for statistical analysis (*p < 0.05, **p < 0.001)



























































































































































































































































































Fig. 5 Effect of Tat on the transcription of mt‑DNA and fusion/fission genes. a qPCR analysis of mRNAs levels from the mtDNA‑encoded genes 
COX‑II, MTND‑2, MTND‑5, MTND‑6, MT‑CYB and MTCO‑3. b qRT‑PCR analysis of mRNAs levels from nuclear DNA‑encoded genes TFAM and NRF1. 
c qRT‑PCR analysis of nuclear‑encoded mRNAs from MFN2 and DNM1L genes, which are involved in mitochondria fusion and fission, respectively. 
Total mRNA from control cells, Jurkat‑Tat72, and Jurkat‑Tat101 cells was analyzed. Nuclear S18 mRNA expression was used as house‑keeping gene. 
All data shown are media and SEM from at least three independent experiments. Statistical significance was calculated by Kruskal–Wallis test with 
Dunn’s multiple comparison post hoc analysis (*p < 0.05, **p < 0.01 ***p < 0.001 vs control)
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was detected in 84.0 % of Jurkat-Tat101 cells but only in 
36  % of control cells. However, ultrastructure changes 
were not detected and in both types of cells the overall 
size and shape of mitochondria were similar, showing 
mitochondria with normal crista, enlarged shape and 
double organelle membrane.
Then, average amount of mitochondria was quantified 
in Tat expressing cells. Jurkat-Tat101 and Jurkat-Tat72 
Table 2 CT and fold expression of mitochondrial nuclear-encoded genes in Jurkat-Tat101 cells
Gene CT Fold of expression Gene CT Fold of expression
JJ-control JJ-Tat101 JJ-Tat101/JJ-control JJ-control JJ-Tat101 JJ-Tat101/JJ-control
AIFM2 26.97 29.28 0.85 SLC25A17 20.72 21.95 2.05
AIP 19.44 20.72 1.74 SLC25A19 21.54 22.58 3.28
BAK1 22.30 23.80 1.49 SLC25A2 28.58 28.95 1.90
BBC3 28.93 30.27 1.66 SLC25A20 22.77 23.92 1.68
BCL2 23.63 24.71 2.00 SLC25A21 27.02 28.34 1.87
BCL2L1 22.90 24.42 1.47 SLC25A22 23.78 24.95 2.05
BID 17.96 19.14 1.86 SLC25A23 25.51 26.55 2.43
BNIP3 18.59 19.68 1.98 SLC25A24 21.17 21.96 2.17
CDKN2A Undetermined Undetermined 1.83 SLC25A25 23.91 24.87 1.00
COX10 23.44 24.64 2.10 SLC25A27 37.15 37.16 4.19
COX18 23.24 24.24 1.21 SLC25A3 16.89 17.98 1.97
CPT1B 30.36 32.16 1.61 SLC25A30 23.34 24.41 2.00
CPT2 21.88 23.27 2.03 SLC25A31 32.62 32.78 3.77
DNM1L 20.42 21.47 1.58 SLC25A37 21.47 22.65 1.86
FIS1 19.89 21.31 2.03 SLC25A4 21.93 22.96 2.06
TIMM10B 21.92 22.98 1.73 SLC25A5 16.59 18.12 1.45
GRPEL1 19.53 20.81 1.80 SOD1 16.03 17.40 1.63
HSP90AA1 15.48 16.70 1.80 SOD2 19.48 20.69 1.82
HSPD1 16.17 17.39 2.13 STARD3 23.29 24.53 1.78
IMMP1L 20.91 21.90 1.52 TAZ 21.59 23.00 1.59
IMMP2L 22.01 23.48 1.99 TIMM10 17.79 19.19 1.59
LRPPRC 19.33 20.41 1.97 TIMM17A 19.38 20.67 1.71
MFN1 21.42 22.52 1.84 TIMM17B 20.85 22.26 1.59
MFN2 21.75 22.95 1.85 TIMM22 22.65 23.73 1.99
MIPEP 23.34 24.52 1.85 TIMM23 19.48 20.69 1.82
MPV17 21.24 22.43 1.61 TIMM44 21.38 22.68 1.70
MSTO1 22.30 23.68 1.59 TIMM50 19.19 20.29 1.96
MTX2 20.15 21.56 3.68 TIMM8A 20.40 21.65 1.77
NEFL 32.20 32.39 1.97 TIMM8B 17.59 18.94 1.65
OPA1 20.33 21.43 2.62 TIMM9 24.46 25.37 2.23
PMAIP1 21.54 22.22 1.73 TOMM20 17.88 19.14 1.75
RHOT1 20.37 21.66 1.72 TOMM22 17.92 19.41 1.50
RHOT2 21.68 22.97 1.73 TOMM34 20.85 22.18 1.67
SFN 25.74 27.02 1.95 TOMM40 20.69 22.37 1.31
SH3GLB1 20.52 21.63 1.47 TOMM40L 23.80 24.95 1.89
SLC25A1 19.77 21.29 1.04 TOMM70A 19.70 20.78 1.99
SLC25A10 25.56 27.57 1.84 TP53 22.63 23.91 1.73
SLC25A12 21.66 22.85 2.02 TSPO 30.82 34.61 0.31
SLC25A13 24.15 25.21 1.94 UCP1 26.98 28.95 1.07
SLC25A14 22.35 23.46 1.83 UCP2 19.92 21.44 1.46
SLC25A15 21.18 22.38 1.99 UCP3 27.19 27.84 2.69
SLC25A16 21.68 22.76 1.80 UXT 18.46 19.73 1.74
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cells were transfected with pAcGFP1-Mito vector that 
encodes a green fluorescent protein (GFP) fused with a 
precursor of the cytochrome c oxidase VIII subunit in 
order to quantify the average amount of mitochondria. 
As mitochondrial pre-proteins are rapidly degraded 
in the cytoplasm by proteasomes when they are not 
properly imported into the mitochondria, GFP from 
pAcGFP1-Mito vector only occurs when the protein 
targets the mitochondria [41]. G-mean of green fluores-











Fig. 6 Expression of an array of nuclear‑encoded genes related to mitochondria in Jurkat‑Tat101 cells. The expression of mitochondrial genes 
encoded by nuclear DNA was analyzed by qRT‑PCR in total RNA from Jurkat‑Tat101 cells versus controls cells, using RT2 Profiler™ PCR Array Human 
Mitochondria. a Relative expression levels of mitochondrial‑related genes deregulated at least ±2.0‑fold in Jurkat‑Tat101 cells versus control 
cells. Table 2 includes the relative gene expression levels of 84 mitochondrial‑genes included in the analysis. b Network of predicted interactions 
between mitochondria‑related genes deregulated ±2.0‑fold in Jurkat‑Tat101. Medium confidence score level was 0.400. Data supporting protein–
protein interactions derived from experimental studies (dark purple lines), homology (light purple lines), databases (light blue lines), text mining (light 
green lines), concurrence (dark blue lines) and co‑expression (black lines). Node colour is arbitrary
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5.17-fold in Jurkat-Tat101 cells but only 2.35-fold in Jur-
kat-Tat72 cells, as compared to control cells (p  <  0.005) 
(Fig. 8c). The levels of two mtDNA-segments that match 
with the area of COX-II and MTND-2 genes were meas-
ured by qPCR. The amount of mtDNA COX-II and 



















































































Fig. 7 Effect of intracellular Tat expression on cellular polarization and the expression of cytoskeleton‑related proteins. a Network of predicted 
interactions between cytoskeletal network proteins deregulated in Jurkat‑Tat101 vs control cells (as specified in Table 3). Medium confidence score 
level was chosen (0.400). Data supporting protein–protein interactions derived from experimental studies (dark purple lines), homology (light purple 
lines), databases (light blue lines), text mining (light green lines), concurrence (dark blue lines) and co‑expression (black lines). Node colour is arbitrary. 
b Rac1 and RhoA GTPases activations were measured using a luminescence‑based assay. Data shown are absolute RLUs from three independent 
experiments. c Cdc42 GTPase activation was measured in protein extracts using a colorimetric‑based assay. Data shown are absolute absorbance at 
490 nm from three independent experiments. d Cellular polarization was studied by immunofluorescence in Jurkat‑Tat72, Jurkat‑Tat101 and control 
cells adhered to fibronectin using an antibody against α‑tubulin and a secondary antibody conjugated with Alexa‑555. e Analysis of migration 
capacity in Jurkat‑Tat72 and Jurkat‑Tat101 in comparison with control cells in the absence of any migratory stimuli. The relative increase of migrated 
events in comparison with control cells from three independent experiments is shown. Statistical significance was calculated with Kruskal–Wallis 
test with Dunn’s multiple comparison test (***p < 0.001 vs control)
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(p  <  0.005), while it only occurred in COX-II mtDNA 
fragment in Jurkat-Tat72 cells (p  <  0.05) (Fig.  8d). This 
result confirms data from Fig.  2a showing enhanced 
mitochondria content in Jurkat-Tat cells.
PBLs expressing Tat-101 showed decreased synthesis 
of ATP and enhanced levels of lactate
PBLs are a more physiological cellular system than T 
CD4+ Jurkat lymphocytes. Representative data were 
Table 3 Selection of proteins deregulated at least ±2.0-fold in Jurkat-Tat101 versus control cells
Only proteins related to actin and tubulin cytoskeleton networks were selected. All peptides selected showed 95 % probability for protein expression and a minimum 
X‑corr of 1.75




Biological process Peptide sequence X-corr
CORO1A Coronin‑1A 9.3 36.8 Actin cytoskeleton organization KLQATVQELQK 2.93
MYL12B Myosin regulatory light 
chain 12B








SEPT2 Septin‑2 0.0 5.2 Actin cytoskeleton organization TMLITHMQDLQEVTQDLHYENFR 2.29
CFL1 Cofilin‑1 0.9 5.2 small GTPase signal transduction LGGSAVISLEGKPL 2.33




TUBB2C Tubulin beta‑2C 6.4 4.4 Microtubule organization INVYYNEATGGK 1.75
SLC9A3R1 Na/H exchange regulatory 
cofactor (NHE‑RF1)




PPP1R12A Protein phosphatase 1 
regulatory subunit 12A
5.2 2.8 Actin cytoskeleton organization NKETLIIEPEKNASR 2.12
TPM4 Tropomyosin alpha‑4 chain 9.9 2.2 Actin cytoskeleton organization KIQALQQQADEAEDR 1.65
2.13
TBCA Tubulin‑specific  
chaperone A




VIM Vimentin 3.9 2.2 Cytoskeleton organization FADLSEAANR 1.75
GDI2 Rab GDP dissociation 
inhibitor beta
0.0 2.0 small GTPase signal transduction MTGSEFDFEEMKR 1.78






















ARHGDIB Rho GDP‑dissociation 
inhibitor 2
−2.6 −10.0 small GTPase signal transduction TLLGDGPVVTDPKAPNVVVTR 1.97
STMN1 Stathmin −28.5 −30.5 Microtubule depolymerization RAsGQAFELILsPR 2.19
TMSL3 Thymosin beta‑4‑like 
protein 3
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a Phenotypes of mitochondria distribu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Fig. 8 Effect of intracellular Tat expression on mitochondrial mass and its subcellular distribution. a Mitochondria distribution within Jurkat‑101 vs 
control cells was analyzed by microscopy after staining with Mitotracker probe. The nucleus was stained with DAPI. Representative images of a cell 
with homogeneous and polarized mitochondrial mass distribution are shown. The graph includes the percentage of each phenotype in Jurkat‑
Tat101 and control cells. b Mitochondria network distribution was also analyzed by electron microscopy using ultrathin sections. Representative 
images from control and Jurkat‑Tat101 cells showing the homogeneous and polarized mitochondrial network distribution are shown. Scale bar 
corresponds to 200 nm. The graph shows the percentage of each phenotype in Jurkat‑Tat101 and control cells. c Expression of the nuclear‑encoded 
VIII sunit of the cytochrome c oxidase was analyzed by flow cytometry in Jurkat‑Tat72, Jurkat‑Tat101 and control cells transfected with a vector 
coding for this protein bound to GFP (pAcGFP1‑Mito). Graph shows G‑mean of green fluorescence intensity of the living cell population from three 
independent experiments. Statistical significance was calculated with Kruskal–Wallis test with Dunn’s multiple comparison test (*p < 0.05 and 
***p < 0.001). d qPCR measurement of mitochondria DNA matching with regions coding for COX‑II and MTND‑2 genes. Nuclear‑encoded DNA S18 
was used as house‑keeping gene. Data shown are media and SEM from three independent experiments. Statistical significance was calculated with 
Kruskal–Wallis test with Dunn’s multiple comparison test (*p < 0.05 and **p < 0.01)
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confirmed using peripheral blood lymphocytes (PBLs) 
from healthy donors that were transfected with a vector 
expressing Tat101 protein or with pcDNA3 as negative 
control. pEGFP vector was co-transfected to measure 
the transfection efficiency, which was 15  % in all cases 
(Fig.  9a). Nuclear localization of intracellular Tat was 
confirmed by immunofluorescence. The intracellular 
levels of ATP were significantly 2.12-fold reduced in 
PBLs transiently expressing intracellular full-length Tat 
(p < 0.05) (Fig. 9b).
Relative data showing lactate concentrations in PBLs 
expressing Tat after normalization with lactate concen-
trations in control PBLs from the same donor are shown. 
In PBLs transiently expressing Tat101, intracellular and 
extracellular lactate levels increased 1.54- and 1.60-
fold (p  <  0.05), respectively (Fig.  9c, d). Relative instead 
of absolute experimental data are shown because both 
intracellular and extracellular lactate concentrations var-
ied among independent donors, but the same tendency 
was observed in each experiment. These results support 
our previous findings in Jurkat-Tat101 cells shown in 
Fig. 2.
HIV-infected T lymphocytes shared some mitochondrial 
alterations with Tat expressing cells
The importance of Tat in modifying mitochondrial main 
functions was evaluated in the context of viral replica-
tion. Jurkat cells were infected by electroporation with 
the Tat-defective viral genome pNL4.3-TatM1I [15] along 
with pTat101 or pcDNA3 as control vector. pEGFP vec-
tor was co-transfected to measure the transfection effi-
ciency, which was 21 and 25  % in control cells and in 
HIV-infected cells, respectively (Fig.  10a, upper panel). 
HIV-1 replication was assessed by quantifying p24/Gag 
levels in the culture supernatants (Fig. 10a, lower panel). 
The levels of p24/Gag increased 652.9-fold in transfected 
with NL4.3-TatM1I and expressing Tat101 versus control 
cells infected only with defective NL4.3-TatM1I. Control 
cells expressed similar levels of p24/Gag than cells trans-
fected with pcDNA3 alone (data not shown). As HIV-1 
replication occurred from vector expression, expression 
levels of Tat in pNL4.3-TatM1I transfected Jurkat cells 
were compared to Tat levels in Jurkat cells infected with 
HIV-1. Immunoblotting analysis showed that Tat expres-
sion levels were 2.0-fold increased in Jurkat cells trans-
fected with pNL4.3-TatM1I along with pCMV-Tat101 
vectors in comparison to Tat levels in Jurkat cells infected 
with NL4.3 virions (Additional file  1: Fig.  S1a). Accord-
ingly, HIV-1 replication, measured by quantifying p24/
Gag levels in the culture supernatant, was also 3.3-fold 
enhanced in transfected versus infected cells (Addi-
tional file 1: Fig. S1b). These data suggest that Tat expres-
sion from transfection or infection may be equivalent in 
Jurkat cells. Neither Tat expression nor HIV-1 replication 
were found in non-infected Jurkat cells or in Jurkat cells 
transfected with pNL4.3-TatM1I along with pcDNA3 
(Additional file 1: Fig. S1a, b).
The intracellular levels of ATP were 1.73-fold reduced 
in HIV-1 infected cells (p < 0.001) (Fig. 10b). The GSH/
GSSG ratio was significantly 2.22-fold reduced (p < 0.05) 
(Fig.  10c) and caspase-3/7 activation was 1.52-fold 
enhanced (p < 0.05) (Fig. 10d) in HIV-1 infected cells.
Mitochondrial content was measured by quantifying 
the levels of two mtDNA-segments matching with COX-
II and MTND-2 genes and was 1.35-fold enhanced in 
HIV-infected cells (p < 0.05) (Fig. 10f ). These data suggest 
that intracellular Tat101 is responsible for reduced ATP 
levels, caspase-3/7 activation and enhanced mitochon-
drial content during HIV-1 infection in T lymphocytes.
Discussion
Mitochondrial OXPHOS is altered in PBMCs from naïve 
patients [6, 7], demonstrating that HIV-1 replication per 
se results in mitochondrial damage independent of ART. 
In this work, we show that intracellular expression of 
Tat101 partly leads this process.
The expression of nuclear encoded genes involved 
in mitochondrial functions was upregulated in Jurkat-
Tat101 cells but the transcription of mtDNA genes was 
dramatically resulting in the impairment of mitochondria 
functions. This lack of coordination between mtDNA 
and nuclear genes expression may also result in a defec-
tive OXPHOS [42]. Accordingly, complex-I and complex-
V were inhibited in Jurkat-Tat101 cells. During HIV-1 
infection, the inhibition of complex-I activity reduces the 
levels of ATP, although ATP synthesis does not stop com-
pletely [8]. Furthermore, the reduction of ATP activates a 
phosphofructokinase that finally increases the concentra-
tion of intracellular lactate [43]. Indeed, ATP levels were 
reduced and subsequently intracellular lactate was accu-
mulated in the cytoplasm of PBLs transiently expressing 
Tat, CD4+ T cells expressing Tat101 and HIV-1 infected 
T cells. The modest effect of Tat observed in PBLs was 
probably due to lower transfection efficiency. It results in 
the dilution of Tat-mediated effects in the whole popu-
lation of PBLs, as most of them were not expressing Tat 
intracellularly.
Lactate can trigger the degradation of IκBα, result-
ing in the autocrine activation of the transcription fac-
tor NF-κB [44], which is essential for HIV-1 replication 
and gets activated upon intracellular Tat expression [14, 
15, 45]. Intracellular lactate levels are secondly regulated 
by the use of the specific monocarboxylate transporter 
1 (MCT1) that allows the diffusion of the lactate out of 
the cells [46]. Extracellular amounts of lactate did not sig-
nificantly change in Jurkat-Tat cells, suggesting that high 
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amounts of lactate can be supported without resulting 
in toxicity. However, enhanced lactate release was found 
in PBLs from healthy donors expressing Tat protein and 
in HIV-1 infected cells, reducing the possibility that Tat 
modifies the MCT1 during HIV-1 infection. Elevated 
lactate in blood is a noticeable toxic effect of ART and 
is used to define mitochondrial toxicity in treated HIV-1 
patients [47].
Compensatory mechanisms for mitochondria toxicity, 
including mtDNA increase, have been shown in different 
subsets of human cells subjected to ART [47–49]. How-
ever, PBMCs from naïve patients show mtDNA depletion 
[6]. Here, we demonstrated that Tat101 increased the 
mitochondria content in T lymphocytes but not enough 
to compensate mitochondria impairment. Other discrep-
ancies regarding mtDNA content have been described 
in adipose tissues from non-treated HIV-1 patients [50, 
51], suggesting that the effect of HIV-1 on mitochondria 
may depend on connected factors that remain to be fully 
elucidated. Here, an increase of mitochondria content 
was described in HIV-1 infected cells, contrary to Jur-
kat-Tat101 cells. This finding suggests that during HIV-1 
replication other viral proteins compensate Tat-mediated 
mitochondrial impairment, although not completely as 
ATP synthesis was also compromised in HIV-1 infected 
T cells.
In Jurkat-Tat101 cells, a compensatory mechanism 
may be changing the cellular preferred metabolism into 
aerobic glycolysis through a generalized up-regulation 
of glycolytic enzymes. Indeed, HIV-1 infected cells show 
a metabolic reprogramming that reduces the energy 
production from the tricarboxylic acid cycle to aerobic 
glycolysis [52, 53]. The aerobic glycolysis is a metabolic 
program, occurring usually in activated lymphocytes [25, 
54], in which the lactate is produced in the presence of 
oxygen, to differentiate it from the anaerobic fermenta-
tion of glucose to lactate that arose from faults in respira-
tion [24]. As it was discussed above, lactate production 
was enhanced in Jurkat-Tat101 cells, PBLs expressing 
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Fig. 9 Intracellular ATP production and intracellular lactate levels and release in PBLs expressing Tat101. Resting PBLs were transiently trans‑
fected with vectors CMV‑Tat101 or pcDNA3, as negative control, along with pEGFP expression vector, as control of transfection efficiency. a Flow 
cytometry quantification of the percentage of living cells expressing EGFP was used to analyze transfection efficiency. Intracellular expression of Tat 
and nuclear subcellular localization were confirmed by immunofluorescence using a monoclonal antibody against Tat and a secondary antibody 
conjugated to Alexa 546. DAPI was used for nuclear staining. b ATP production was measured by chemiluminescence using a commercial assay. 
Data shown are RLUs mean and SEM of concentration from five independent experiments. c Relative intracellular lactate production measured in 
PBLs expressing Tat versus control PBLs. Data shown are relative mean and SEM of concentration from five independent experiments. d Relative 
release of lactate to the culture medium measured in the same PBLs expressing Tat used to measure intracellular lactate. Statistical significance was 
calculated by Mann–Whitney test (*p < 0.05)
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Fig. 10 Intracellular ATP levels, GSH/GSSG ratio, caspase‑3/7 activation, mtDNA transcription and mitochondrial content in HIV‑1 infected T 
lymphocytes. PBLs were infected pNL4.3‑TatM1I vector along with pcDNA3 or with pCMV‑Tat101 vector. pEGFP was co‑transfetion as a control of 
transfection efficiency. a Flow cytometry quantification of the percentage of living cells expressing EGFP was used to analyze transfection efficiency 
(upper panel). Quantification of p24/Gag in culture supernatant was used as control of infection (lower panel). b Intracellular ATP production. c 
Intracellular concentration of GSH/GSSG. d Caspase‑3/7 activation. Intracellular ATP, GSH/GSSG ratio and caspase‑3/7 activation were measured by 
chemiluminescence using commercial assays. e qPCR analysis of mRNAs levels from the mtDNA‑encoded genes MTND‑2 and COX‑II. mRNA levels 
of nucelar‑encoded S18 expression were used as house‑keeping gene. f qPCR analysis of mitochondria DNA matching with regions coding for 
COX‑II and MTND‑2 genes. Nuclear‑encoded DNA S18 was used as house‑keeping gene. Data shown are mean and SEM from three independent 
experiments. Statistical significance was calculated by Mann–Whitney test or Kolmogorov–Smirnov test (*p < 0.05, **p < 0.01)
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suggest that the main breakdown point may include the 
synthesis of pyruvate and the intermediate metabolite 
glyceraldehyde 3-phosphate (G3P), probably through a 
dramatic repression of GAPDH. Additionally, intracellu-
lar Tat101 enhanced the expression of PKM2 and LDHB, 
which together increase the conversion of lactate from 
pyruvate in the cytoplasm. PKM2 is crucial for metabo-
lism shift during HIV-1 pathogenesis, as up-regulation 
of PKM2 has been observed in different types of HIV-1 
infected cells [52, 55, 56]. In contrast to OXPHOS, glyco-
lysis is energetically inefficient, theoretically yielding two 
molecules of ATP per glucose molecule consumed com-
pared to thirty-six if it is fully oxidized. However, aero-
bic glycolysis has the energetic advantage of generating 
ATP at higher speed than OXPHOS [57]. Therefore, acti-
vated lymphocytes do not activate aerobic glycolysis only 
because their capacity for OXPHOS is saturated but also 
to provide sufficient ATP to support the cellular growth 
and proliferation [58–60]. In summary, aerobic glycolysis 
may be activated in Jurkat-Tat101 cells as a complemen-
tary source of ATP production.
Increased production of ROS due to diminished com-
plex I activity and subsequent reduction in ATP levels 
has been extensively described in infected CD4+ T cells 
[8]. Indeed, extracellular Tat is known to increased gen-
eration of ROS and caspase-3/7 activation in the intesti-
nal mucosa of HIV-infected patients [20]. In this work, it 
is shown that intracellular Tat101 increased ROS produc-
tion and apoptosis induction, and both processes were 
coupled. However the GSH/GSSG ratio was balanced 
in Jurkat-Tat101 cells despite of the chronic oxidative 
stress detected in HIV-1 infected lymphocytes. There-
fore, our data cannot point out a role of intracellular Tat 
expression in the overall glutathione imbalanced showed 
in PBLs from HIV-1 infected patients. Because of the 
experimental systems used in this work, we cannot rule 
out the role of other viral proteins in the induction of 
oxidative stress and mitochondrial damage in infected T 
cells. In particular, extracellular Tat and other viral pro-
teins as extracellular Vpr are able to reduce GSH/GSSG 
ratio [20, 61], and may gain value during HIV-1 infection 
in vivo. Although chronic oxidative stress is detected in 
HIV patients [62, 63], most in  vivo studies are focused 
on patients under ART, where viral load is not detectable 
[64–67] and treatment enhances the synergy of HIV and 
oxidative stress [68]. This fact together with the low num-
ber of productively infected lymphocytes in peripheral 
blood HIV-1 in  vivo infection [69, 70] suggest that not 
only HIV-1 replication itself but additional factors may 
contribute to oxidative stress as part of HIV-1 disease 
pathogenesis. This phenomenon may be related to the 
chronic immune activation and senescence produced by 
increased microbial translocation and persistent viremia 
or secondary to the increased rate of opportunistic infec-
tions as it has been described [71–73].
ROS levels are responsible for the profound reorgani-
zation of mitochondria-cytoskeletal interactions found in 
HIV-1 patients [7]. Furthermore, ROS lead to the appear-
ance of dense stress fibers, required for intercellular con-
tacts and migration [74]. In line with it, the mitochondria 
network of Jurkat-Tat101 cells was localized at one edge 
of the lymphocyte, reflecting the acquisition of a polar-
ized shaped and probably as a host defense response to 
supply enough energy to the migration process. Because 
mitochondria are transported to the uropod along micro-
tubules [38], it seems that microtubule dynamics are per-
severed in Jurkat-Tat cells for mitochondria trafficking 
and delocalization at the uropod. Furthermore, profound 
actin cytoskeleton changes may also be responsible for 
Tat-mediated mitochondria delocalization. For instance, 
intracellular Tat101 activated RhoA and Rac1, actin 
remodeling GTPases that control mitochondria traffick-
ing [75], probably through the depletion of ARHGDIB, a 
protein that promotes the misfolding and degradation of 
the cytosolic pool of Rho GTPases together with the acti-
vation of the remaining membrane bound pool [76, 77]. 
Accordingly, mitochondria proteome from HIV-infected 
patients are enriched in actin proteins [7], including 
the GTPase Rab1, which regulates organelle tether-
ing through the enhancement of Rab GDP dissociation 
inhibitor beta protein (GDI2) [78], a modulator of Rab 
recycling that is up-regulated in Jurkat-Tat cells. Eventu-
ally, mitochondria accumulation also requires an unper-
turbed balance between fusion and fission processes [38], 
which might occur in Jurkat-Tat101 cells as the expres-
sion of pro-fusion MFN2 and pro-fission DNM1L genes 
were not deregulated.
It is to notice that Tat is indispensable for HIV-1 repli-
cation [13, 79, 80] and it is not packaged inside the viri-
ons [81]. Accordingly, NL4.3-TatM1I strain lacking Tat 
protein did not yield productive infection. Therefore only 
the transfection approach based on co-expressing NL4.3-
TatM1I strain and Tat101 allowed a proper assessment of 
the impact of Tat on the different mitochondrial param-
eters during HIV-1 replication. Therefore, results from 
Jurkat expressing only intracellular Tat do not always 
correlate with data from infection, where other viral pro-
teins exert compensatory mechanisms to success viral 
replication.
Conclusions
This work shows the influence of intracellular HIV-1 Tat 
protein on mitochondrial overall functions in Jurkat cells 
and PBLs. Tat101 polarized the mitochondria distribu-
tion and increased the mitochondrial content, probably 
to compensate mtDNA transcription impairment and 
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low ATP production. Tat101 also enhanced the expres-
sion of metabolism-related proteins and mitochondrial-
related genes. The presence of Tat second exon increased 
these effects, confirming that full-length Tat mostly 
regulated the non-transcriptional functions of the pro-
tein. The intracellular expression of Tat may be respon-
sible for the mitochondrial dysfunctions found in HIV-1 
infected patients as for instance OXPHOS impairment 
and increased mtDNA content and therefore Tat may 




Jurkat TetOff cell line was purchased from BD Bio-
sciences Clontech (Mountain View, CA, USA). The high-
level gene expression TetOff system [82], which keeps 
the expression of the gene cloned in pTRE2hyg vector 
continually turned on. Unlike other inducible mamma-
lian expression systems, gene regulation in the Tet sys-
tems is highly specific, so the interpretation of results 
would not be hindered by pleiotropic effects or nonspe-
cific induction (Yin et  al. 1996). The vector pTRE2hyg-
Tat101 expressed a complete HIV-1 tat gene (aa 1–101), 
obtained from pCMV-Tat101 vector [83], after cloning in 
pTRE2hyg vector (Clontech, BD Tet-Off gene expression 
System, BD Biosciences). Complementary DNA (cDNA) 
from tat first exon (1–219nt; 1–72aa) was obtained from 
pCMV-Tat101 vector using specific oligonucleotides to 
introduce a stop codon at residue 73, and then cloned in 
pTRE2hyg vector. Jurkat TetOff was transfected by elec-
troporation with pTRE2hyg-Tat72 or pTRE2hyg-Tat101 
vectors and these cell lines were stabilized with hygro-
mycin B as previously described [14, 16]. The empty 
pTRE2hyg vector was transfected and stabilized in the 
Jurkat TetOff cell line into obtained negative control 
cells. Jurkat-Tat101 and Jurkat-Tat72 cells are not clone 
populations but a mixed population in which more than 
75  % of the cells express high intracellular amounts of 
Tat101 (full-length) or Tat72 (first exon) protein which 
were equivalent to Tat levels detected in T lymphocytes 
infected with the HIV-1 infectious clone NL4.3wt [16]. 
All Jurkat cells were cultured in RPMI 1640 medium 
(Biowhittaker, Walkersville, MD, USA) with 10  % fetal 
calf serum (PAN Biotech GmbH, Aidenbach, Germany), 
2  mM  l-glutamine, 100  μg/ml streptomycin and 100 
U/ml penicillin (Lonza, Basel, Switzerland), 300  μg/ml 
geneticin and 300 μg/ml hygromycin B (BD Biosciences 
Clontech), at 37  °C and 5  % CO2. Serum depletion was 
performed 3  h before each experiment. PBLs were iso-
lated from blood of healthy donors by centrifugation 
through a Ficoll-Hypaque gradient (Pharmacia Corpo-
ration, North Peapack, NJ, USA) and cultured in RPMI 
1640 medium supplemented with 10  % (v/v) fetal calf 
serum (FCS), 2 mM l-glutamine, 100 μg/ml streptomy-
cin, 100 U/ml penicillin (Biowhittaker, Walkersville, MD, 
USA).
Antibodies, reagents and vectors
Anti-tubulin, MitoTracker CMxRos probe (0.2 μM) and 
4′,6-diamidino-2-phenylindole (DAPI) were purchase 
from Sigma-Aldrich. Antibody against HIV-1 Tat was 
obtained from Advanced Biotechnologies Inc. (Colum-
bia, MD, USA). pCMV-Tat101 vector expresses HIV-1 
Tat101 protein [84]. pAcGFP1-Mito vector (BD Bio-
sciences, Erembodegem, Belgium) encodes the GFP 
derived from Aequorea coerulescens fused at its N-ter-
minus with a precursor of the cytochrome c oxidase VIII 
subunit [41].
Proteome analysis and criteria for protein identification
Proteome analysis was performed as previously described 
[15]. Briefly, 200  μg of trypsin-digested proteins were 
loaded into the LC–MS/MS system and analyzed using a 
C-18 reversed phase nano-column (Thermo-Fisher, San 
Jose, CA, USA). Real-time ionization and peptide frag-
mentation was performed on an orbital ion trap mass 
spectrometer (LTQ Orbitrap XL, Thermo Fisher Sci-
entific, San Jose, CA, USA) [85]. For peptide database 
searching, tandem mass spectra were analysed using 
Sequest (Thermo Fisher Scientific; version 1.3.0.339) 
and X! Tandem (http://www.thegpm.org; version 
CYCLONE). Sequest and X! Tandem were searched with 
a fragment ion mass tolerance of 30 PPM and a parent 
ion tolerance of 15 PPM. Scaffold 3.0 (Proteome Software 
Inc., Portland, OR, USA) was used to validate peptide 
identifications. Only peptide established at a probabil-
ity greater than 95 % and with XCorr-score values above 
1.75 were accepted. Proteins related to mitochondria 
and cytoskeleton that changed at least ±2.0-fold in Jur-
kat-Tat101 were selected and subjected to analysis with 
STRING 9.0 database (http://string-db.org/) [86].
PCR and RT-PCR assays
DNA and total RNA was isolated with QiAmp DNA 
blood mini kit and RNeasy Mini kit (Qiagen, Barce-
lona, Spain), respectively. cDNA was synthesized using 
GoScript Reverse Transcription System (Promega, WI, 
USA). Specific primers are described in Additional file 2: 
Table  S1. The expressions Ribosomal protein S18 (S18) 
was used as housekeeping gene. The PCR amplification 
was performed in a StepOnePlus™ Real-Time PCR Sys-
tems (Applied Biosystems, CA) using SYBR Green. Data 
analysis was performed with 7500 software v2.0.6 and Ct 
values were normalized according to S18 amplification 
and analyzed with the formula 2−∆∆Ct.
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Expression of nuclear-encoded genes related 
to mitochondria
RT2 Profiler™ PCR Array Human Mitochondria (Qia-
gen) is a RT-PCR based array and was used to studied the 
expression of 84 mitochondrial related genes which are 
nuclear encoded. The array also included five housekeep-
ing genes and internal controls for genomic DNA ampli-
fication, reverse transcription and positive PCR controls. 
Genomic RNA elimination and reserve transcription 
was performed using 5 μg of total RNA of Jurkat-con-
trol and Jurkat-Tat101 cells, following manufacturers’ 
instructions. The PCR amplification was performed in a 
StepOnePlus™ Real-Time PCR Systems (Applied Biosys-
tems) using SYBR Green. Data analysis was performed 
accordingly to the instructions detailed in RT2 Profiler™ 
PCR Array Human Analysis Manual. CT higher than 30 
cycles were rejected for further analysis. CT values were 
normalized according to the amplification of five house-
keeping genes included in the array amplification and 
analyzed with the formula 2−∆∆Ct.
Activity of citrate synthase and OXPHOS complexes I and V
The enzymatic activity of citrate synthase (EC 2.3.3.1) 
was measured with Citrate Synthase Assay Kit (Sigma-
Aldrich). Briefly, 1 × 107 cells were lysed with 125 μl of 
CelLytic M cell Lysis Reagent and 10 μl of this lysate was 
incubated with 200 μl of a reaction mix containing acetyl-
coA, DTNB and oxaloacetic acid. Changes in the absorb-
ance at 412  nm were followed in a microplate reader 
Sunrise (Tecan Group Ltd., Männedorf, Switzerland) to 
calculate the units (μmole/ml/min) of citrate synthase 
accordingly to the manufacturer’s instructions. The activi-
ties of complex I (NADH dehydrogenase or ubiquinone 
oxidoreductase, EC 1.6.5.3) and complex V (F1F0 ATPase 
or ATP synthase, EC 3.6.3.14) were measured using com-
plex I Enzyme Activity Microplate Assay Kit (Abcam) 
and ATP synthase (complex V) Human Profiling ELISA 
Kit (Abcam), respectively, according to manufacturer’s 
instructions. Complex I assay is based on the oxidation 
of nicotinamide adenine dinucleotide (NADH) to NAD+ 
and the simultaneous reduction of a dye leading to an 
increase of absorbance at 450 nm, which was measured in 
a microplate reader Sunrise. Briefly, protein from 6 × 106 
cells were extracted by diluting 1/10 the extraction buffer. 
A total of 200 μg of protein from supernatants in 50 μl of 
final volume was added in each well and incubated for 3 h 
at room temperature before accurate washing and adding 
200 μl of assay solution, containing 40 mM NADH. The 
absorbance was measured at 450  nm at approximately 
30 s’s intervals for 30 min. To quantify complex-V activ-
ity, a total of 200 μg of protein extracted 6 ×  106 cells 
was added in each well which is coated with a capture 
antibody specific for human ATP synthase. After 2 h incu-
bation at room temperature and continuous shaking at 
300  rpm, wells were washed and further incubated with 
an anti- ATP synthase detector antibody and then with 
a specific HRP-conjugated antibody. The TMB substrate 
solution and hydrochloric acid used as stopping solu-
tion were added to each well and the color intensity was 
measured at 450  nm using a microplate reader Sunrise. 
To assess OXPHOS complex I and complex V activities, 
absorbance values were normalized accordingly to mito-
chondria content using citrate synthase levels.
ATP and lactate concentrations
Intracellular levels of ATP were determined with CellTi-
ter-Glo® 9 Luminescent Cell Viability Assay (Promega), 
following the manufacturer’s instructions. Briefly, 1 × 105 
cells were incubated for 10 min at room temperature in 
CellTiter-Glo® Reagent, which contained lysis buffer and 
thermostable luciferase and the luminescent signal was 
analyzed in an Orion Microplate Luminometer with Sim-
plicity software (Berthold Detection Systems, Oak Ridge, 
TN, USA). Intracellular and extracellular levels of l-(+)-
Lactate were measured in cell lysates or supernatants 
using Lactate Assay Kit II (Sigma-Aldrich) accordingly 
to manufacturer’s instructions. Briefly, 1 × 106 cells were 
lysed with 4 volumes of lysis buffer or pelleted to collect 
the subsequent supernatant and 50 μl of each sample was 
incubated with the commercial enzyme during 30  min 
at room temperature. The absorbance at 450 nm, which 
was proportional to the lactate concentration, was deter-
mined using in a microplate reader Sunrise.
Intracellular ROS and glutathione levels
Living Jurkat-Tat cells were adhered onto fibronectin-
coated plates and stained with DCF-DA 2′,7′-(5 μM) 
(Sigma-Aldrich), which after oxidation is converted into 
highly fluorescent DCF (2′7′-dichlorofluorescein) [26]. 
Images were obtained with a Leica DMI 4000B Inverted 
Microscope (Leica Microsistemas, Barcelona, Spain). 
Cells from a total of 15 fields from three independ-
ent experiments were analyzed. Fluorescence from cells 
stained with DCF-DA-FITC was also measured by FACS-
calibur Flow Cytometer (BD Biosciences Clontech) using 
FL-1 channel and data were analysed by CellQuest soft-
ware. Intracellular levels of reduced glutathione (GSH) 
and oxidized glutathione (GSSG) were measured using 
the luminescence-based GSH/GSSG-Glo Assay (Pro-
mega). The luminescent signal (relative light units, RLUs) 
was quantified in an Orion Microplate Luminometer 
with Simplicity software and RLUs were converted into 
concentration (pM) using the glutathione standard curve 
included in the assay.
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Apoptosis assays
Living cells were adhered on PolyPrep slides, fixed 
with 2  %-PFA and treated with Dapi (4′,6-diamidino-
2-phenylindole) (Sigma-Aldrich) for staining the nuclei. 
Images were obtained with a Leica DMI 4000B Inverted 
Microscope (Leica Microsistemas, Barcelona, Spain). 
The percentage of apoptotic events was calculated by 
acquiring 60 fields from three independent experi-
ments—containing an average number of cells close to 
40—and considering the total number of cells. Activa-
tion of casapse-3 was measured in non-treated cells with 
CaspaseGlo®3/7 systems (Promega). The luminescent 
signal (relative light units, RLUs), which was directly 
proportional to caspase activation, was quantified in an 
Orion Microplate Luminometer with Simplicity soft-
ware (Berthold Detection Systems). Cells were stained 
with Annexin-V-PE (Immunostep, Salamanca, Spain) to 
measure apoptosis commitment. Cells were co-stained 
together with DCF-DAC and Annexin-V-PE to meas-
ure the co-localization of apoptosis and ROS produc-
tion. Fluorescence was measured by FACScalibur Flow 
Cytometer (BD Biosciences Clontech) and data were 
analyzed by CellQuest software.
Immunofluorescence and electron microscopy assays
Living cells were stained with MitoTracker Red CMxRos 
Mitochondrial (0.2 μM) and then adhered on PolyPrep 
slides (Sigma-Aldrich) and fixed with 2  % paraformal-
dehyde (PFA) in PBS1x. To study cellular polarization, 
cells were adhered on fibronectin-coated slides, fixed 
with 2 %-PFA and stained with anti-tubulin by immuno-
fluorescence assay previously described [14]. Nuclei were 
stained using 4′,6-diamidino-2-phenylindole (Dapi) from 
Sigma-Aldrich. Cells from a total of 15 fields from three 
independent experiments were analyzed. Images were 
obtained with a Leica DMI 4000B Inverted Microscope 
(Leica Microsistemas, Barcelona, Spain). For electron 
microscopy ultrastructural analysis, cells were fixed with 
a mixture of 2 % glutaraldehyde and 4 % PFA 0.1 M phos-
phate buffer (pH 7.4) for 2 h at 4 °C, washed three times 
in phosphate buffer; and postfixation was performed 
with a 1 % osmium tetroxide and 1 % potassium ferricya-
nide and 0.15  % tannic acid. Samples were treated with 
2 % uranyl acetate and dehydrated in increasing concen-
trations of ethanol (50, 75, 90, 95, and 100  %). Finally, 
infiltration in epoxy-resin was done using increasing con-
centrations of resin (25, 50, 75 and 100 %) and polymeri-
zation was performed at 60 °C. Ultrathin sections of the 
samples were stained with saturated uranyl acetate and 
2  % lead citrate following standard procedures and sec-
tions were imaged with a Tecnai 12 FEI microscope (FEI, 
Hillsboro, Oregon, USA) operated at 120 kV.
Activation of small GTPases and cellular migration
Rac1 and RhoA GTPase activation was measured using 
G-LISATM Rac1 activation Assay Biochem Kit™ and 
G-LISA™ RhoA activation Assay Biochem KitTM (Cys-
toskeleton, Denver, CO, USA), which are luminescence 
based. Cdc42 GTPase activation was measured with the 
colorimetric assay G-LISATM Rac1 activation Assay Bio-
chem Kit™ (Cystoskeleton). Migration of living cells was 
allowed for 2 h at 37 °C with 5 % CO2 in transwell plates 
with 5  μm-pore filters (Costar, Cambridge, MA, USA) 
and quantified by flow cytometry.
HIV-1 infection
Jurkat cells were in  vitro infected by electroporation. 
pNL4.3-TatM1I vector was co-transfected along with 
pCMV-Tat101 in a proportion 2:1 as previously described 
[15]. pNL4.3-TatM1I vector is similar to pNL4.3 wildtype 
but contains a point mutation in the start codon of the 
tat gene, and therefore it is not able to infect produc-
tively [15]. pCMV-Tat101 vector expresses HIV-1 Tat101 
wild type protein [84]. pNL4.3-TatM1I vector co-trans-
fected with pcDNA3 vector was used as negative con-
trol. pEGFP vector (BD Biosciences Clontech) was used 
as control of transfection efficiency. The production of 
infectious HIV-1 progeny was confirmed by quantify-
ing the levels of p24/Gag in the culture supernatant 48 h 
post-transfection.
Quantification of Tat levels in HIV-1 infected cells
Briefly, infectious supernatants were obtained from cal-
cium phosphate transfection of HEK293T cells with 
pNL4.3-wt plasmid. Jurkat cells were infected with 10 ng 
of p24/Gag equivalent of NL4.3 strain per million cell by 
spinoculation during 30 min at gently rotation and room 
temperature. Non-infected Jurkat cells were used as neg-
ative control. Jurkat cells were also infected by electropo-
ration. pNL4.3-TatM1I vector was co-transfected along 
with pCMV-Tat101 or with pcDNA3 vector as negative 
control. pEGFP vector was used as control of transfec-
tion efficiency. Whole protein extracts were obtained 
5  days post-infection and 100  ug were fractionated by 
sodium dodecyl sulfate–polyacrilamide gel electrophore-
sis (SDS–PAGE). Expression levels of Tat were analyzed 
by immunobloting analysis (western-blot) using mouse 
monoclonal antibody to HIV-1 Tat regulatory protein (aa 
1–16) (Biotechnologies, ABI, Columbia). Images were 
acquired in a BioRad Geldoc 2000 and densitometry was 
performed with Quantity One software (BioRad Labora-
tories, Madrid, Spain) with Quantity One software. The 
relative ratio of the optical density units corresponding to 
each sample was calculated regarding the internal control 
of each lane after subtracting background noise.
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Statistical analysis
Statistical analysis was performed using Graph Pad Prism 
5.0 (San Diego, CA, USA). Comparisons among control, 
Jurkat-Tat72 and Jurkat-Tat101 cells were made using non-
parametric Kruskal–Wallis test with Dunn’s Multiple Com-
parison post hoc analysis. Non-parametric Mann–Whitney 
test was used to compare PBLs expressing or not Tat101 
and HIV-1 infected cells versus control. Non-parametric 
Kolmogorov–Smirnov test was used to compared DNA and 
RNA PCRs data in HIV-1 infected cells versus control, as 
normalized data yielded the same value in control cells. The 
p values (p) <0.05 were considered statistically significant.
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